Technical Analysis for CRY - CryoLife, Inc. Common Stock

CRY closed up 0.99 percent on Wednesday, July 23, 2014, on 77 percent of normal volume.

Next earnings date: 2014-07-24

Rating Last Price % Change $ Change Track This Stock
grade D $9.55 4.20% 0.385 + Watchlist + Portfolio
Technicals
Current Trend Strength: Weak or Absent
Long-Term Intermediate-Term Short-Term
Down Up Up
See historical CRY trend table...

Date Name Bull/Bear
2014-07-23 Bollinger Band Squeeze Range Contraction
2014-07-22 NR7 Range Contraction
2014-07-22 Bollinger Band Squeeze Range Contraction
2014-07-21 50 DMA Support Bullish
2014-07-21 Bollinger Band Squeeze Range Contraction
2014-07-18 Upside 50 DMA Break Bullish
2014-07-18 Bullish Engulfing Bullish
2014-07-18 Bollinger Band Squeeze Range Contraction
2014-07-17 Downside 50 DMA Break Bearish
2014-07-17 Bollinger Band Squeeze Range Contraction

See older technical analysis pattern alerts for CRY ...
Buy or Sell?
Is CRY a Buy, Sell or Hold?:

Swing Traders
Bull / Buy Case
Bear / Sell Case
Hold Case
Data

Average Volume: 115,952
Average True Range: 0.27
ADX: 11.76
+DI: 22.77
-DI: 17.6
Chandelier Exit (Long): 8.53
Chandelier Exit (Short): 9.36
52 Week High: 12.14
52 Week Low: 6.01
200-Day Moving Average: 9.61
50-Day Moving Average: 8.91
20-Day Moving Average: 9.02
10-Day Moving Average: 9.09
Upper Bollinger Band: 9.38
Lower Bollinger Band: 8.66
Percent B (%b): 0.7
Bandwidth: 0.08

Profile

Sector: Health Care

Industry: Medical/Dental Instruments

CryoLife, Inc. preserves and distributes human tissues for transplantation in the United States and internationally. The company also develops, manufactures, and commercializes medical devices for cardiac and vascular applications. It distributes CryoValve SG pulmonary heart valves and CryoPatch SG pulmonary cardiac patch tissues that are processed using CryoLifeÂ’s proprietary SynerGraft technology; and vascular tissues comprising CryoVein and CryoArtery to treat various vascular reconstructions, such as peripheral bypass, hemodialysis access, and aortic infections. The company also distributes surgical sealants and hemostats, including BioGlue Surgical Adhesive, an adjunct to sutures and staples for use in adult patients in open surgical repair of vessels, as well as in repair of cardiac, vascular, pulmonary, and additional soft tissues. In addition, its surgical sealants and hemostats comprise BioFoam Surgical Matrix for use as an adjunct in the sealing of abdominal parenchymal tissues, when cessation of bleeding by ligature or conventional methods is ineffective or impractical; PerClot, an absorbable powdered hemostat agent used in surgery; and revascularization technologies, which include transmyocardial revascularization system for treating patients with stable angina that is not responsive to conventional therapy. CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization. The company, through its subsidiary, Hemosphere, Inc., markets HeRO Graft, a solution for end-stage renal disease in certain hemodialysis patients. CryoLife distributes its products through field service representatives, cardiac specialists, direct field representatives, and independent distributors. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

StockTwits
Recent Tweets:


Comments on CRY:
You must be logged in to access portfolios.

Sign up

Login